Medtronic (NYSE:MDT) Given New $93.00 Price Target at Robert W. Baird

Medtronic (NYSE:MDT) had its price objective lifted by Robert W. Baird from $92.00 to $93.00 in a research report released on Wednesday,MarketScreener reports. They currently have a neutral rating on the medical technology company’s stock.

Other equities research analysts have also recently issued reports about the stock. Wall Street Zen cut shares of Medtronic from a “buy” rating to a “hold” rating in a research report on Saturday, April 11th. Sanford C. Bernstein lifted their price target on Medtronic from $111.00 to $112.00 and gave the company an “outperform” rating in a research note on Friday, January 9th. Mizuho cut their price target on Medtronic from $125.00 to $120.00 and set an “outperform” rating on the stock in a report on Monday. Wells Fargo & Company assumed coverage on Medtronic in a research report on Friday, January 30th. They set an “overweight” rating and a $114.00 price objective for the company. Finally, JPMorgan Chase & Co. decreased their price objective on Medtronic from $105.00 to $100.00 and set a “neutral” rating for the company in a report on Wednesday, February 18th. Sixteen equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $109.25.

Medtronic Price Performance

NYSE MDT opened at $87.16 on Wednesday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. The stock has a market cap of $111.91 billion, a price-to-earnings ratio of 24.28, a PEG ratio of 2.28 and a beta of 0.75. The business has a 50 day simple moving average of $92.19 and a 200 day simple moving average of $95.82. Medtronic has a 52-week low of $79.93 and a 52-week high of $106.33.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The company had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. During the same quarter in the prior year, the company earned $1.38 earnings per share. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Analysts anticipate that Medtronic will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, April 17th. Investors of record on Friday, March 27th will be paid a $0.71 dividend. The ex-dividend date of this dividend is Friday, March 27th. This represents a $2.84 annualized dividend and a dividend yield of 3.3%. Medtronic’s dividend payout ratio (DPR) is currently 79.11%.

Insiders Place Their Bets

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the company’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the sale, the executive vice president directly owned 32,768 shares of the company’s stock, valued at approximately $3,201,761.28. This represents a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.26% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Brighton Jones LLC grew its holdings in Medtronic by 1,368.0% during the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock worth $3,194,000 after purchasing an additional 37,265 shares during the period. Sivia Capital Partners LLC raised its stake in Medtronic by 9.6% in the second quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock valued at $380,000 after buying an additional 381 shares during the period. Jump Financial LLC bought a new stake in Medtronic in the second quarter valued at approximately $299,000. Main Street Financial Solutions LLC lifted its position in shares of Medtronic by 28.9% in the second quarter. Main Street Financial Solutions LLC now owns 14,356 shares of the medical technology company’s stock valued at $1,251,000 after buying an additional 3,218 shares during the last quarter. Finally, HUB Investment Partners LLC boosted its stake in shares of Medtronic by 21.3% during the 2nd quarter. HUB Investment Partners LLC now owns 19,226 shares of the medical technology company’s stock worth $1,676,000 after acquiring an additional 3,376 shares during the period. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: MassDevice reports Medtronic posted strong 1?year clinical results for its drug?coated balloon (DCB), which supports growth in peripheral and coronary interventional franchises and can help medium?term revenue/market share. Medtronic has strong 1-year results for drug-coated balloon
• Positive Sentiment: Jim Cramer publicly included MDT among a set of top holdings, a sentiment signal that can support retail investor confidence. Jim Cramer Says “Don’t Mess With Alphabet, They’re Crushing It”
• Neutral Sentiment: Robert W. Baird nudged its price target up slightly to $93 and maintained a neutral rating — a modest vote of confidence but not a catalyst for a meaningful rerating. Baird adjusts Medtronic price target to $93
• Neutral Sentiment: Benzinga highlighted MDT in a dividend?yield discussion, underscoring its appeal to income investors but not changing near?term fundamentals. Wall Street’s Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
• Neutral Sentiment: Sector research presented at EHRA highlights AI and remote monitoring advances (not specific to Medtronic) — relevant for long?term competitive dynamics in cardiac monitoring. EHRA 2026 Studies Reveal Why False Positives Persist in AI-Equipped Implantable Cardiac Monitors
• Negative Sentiment: Truist cut its price target to $95 from $103 and kept a “hold” rating — the downgrade trims upside expectations and is a near?term negative for sentiment. Truist cuts price target on Medtronic to $95 from $103
• Negative Sentiment: Market headlines (Yahoo/Zacks) note MDT shares declined despite broader market gains, reflecting the net effect of the mixed analyst commentary and profit?taking. Medtronic (MDT) Stock Drops Despite Market Gains: Important Facts to Note

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter?defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).